Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence
Cells · 2023
DOI: 10.3390/cells12202438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Ja-Yeol Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Institute for Tumor Research, Chungbuk National University, Cheongju 28644, Republic of Korea. Hauptthemen laut MEDLINE: Adenocarcinoma, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation (NRF) of Korea.
Abstract (Originalsprache)
Oncogenic K-RAS mutations occur in approximately 25% of human lung cancers and are most frequently found in codon 12 (G12C, G12V, and G12D). Mutated K-RAS inhibitors have shown beneficial results in many patients; however, the inhibitors specifically target K-RASG12C and acquired resistance is a common occurrence. Therefore, new treatments targeting all kinds of oncogenic K-RAS mutations with a durable response are needed. RUNX3 acts as a pioneer factor of the restriction (R)-point, which is critical for the life and death of cells. RUNX3 is inactivated in most K-RAS-activated mouse and human lung cancers. Deletion of mouse lung Runx3 induces adenomas (ADs) and facilitates the development of K-Ras-activated adenocarcinomas (ADCs). In this study, conditional restoration of Runx3 in an established K-Ras-activated mouse lung cancer model regressed both ADs and ADCs and suppressed cancer recurrence, markedly increasing mouse survival. Runx3 restoration suppressed K-Ras-activated lung cancer mainly through Arf-p53 pathway-mediated apoptosis and partly through p53-independent inhibition of proliferation. This study provides in vivo evidence supporting RUNX3 as a therapeutic tool for the treatment of K-RAS-activated lung cancers with a durable response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, School of Medicine, Institute for Tumor Research, Chungbuk National University, Cheongju 28644, Republic of Korea.
- Department of Pathology, School of Medicine, Chungbuk National University and Hospital, Cheongju 28644, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, School of Medicine, Chungbuk National University and Hospital, Cheongju 28644, Republic of Korea.
ORCID-Profile: Ja-Yeol Lee, Jung-Won Lee, Seo-Yeong Yoo, Dohun Kim
Förderung
- National Research Foundation (NRF) of Korea
Zitieren
APA
Lee, J. Y., Lee, J. W., Park, T. G., Han, S. H., Yoo, S. Y., Jung, K. M., Kim, D. M., Lee, O. J., Kim, D., Chi, X. Z., Kim, E. G., Lee, Y. S., & Bae, S. C. (2023). Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence. Cells. https://doi.org/10.3390/cells12202438
Vancouver
Lee JY, Lee JW, Park TG, Han SH, Yoo SY, Jung KM, et al. Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence. Cells. 2023. doi:10.3390/cells12202438
BibTeX
@article{Lee2023,
author = {Lee, Ja-Yeol and Lee, Jung-Won and Park, Tae-Geun and Han, Sang-Hyun and Yoo, Seo-Yeong and Jung, Kyoung-Mi and Kim, Da-Mi and Lee, Ok-Jun and Kim, Dohun and Chi, Xin-Zi and Kim, Eung-Gook and Lee, You-Soub and Bae, Suk-Chul},
title = {Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12202438}
}
EUVIMED